scholarly journals Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

2019 ◽  
Author(s):  
Takumi Kishimoto ◽  
Nobukazu Fujimoto ◽  
Takeshi Ebara ◽  
Toyonori Omori ◽  
Tetsuya Oguri ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Malignant Pleural Mesothelioma ◽  
Tissue Damage ◽  
Elevated Serum ◽  
Serum Levels ◽  
Pleural Mesothelioma ◽  
Asbestos Fibers ◽  
Chemokine Ligand ◽  
History Of ◽  
Tumor Types

Abstract Background Malignant pleural mesothelioma (MPM) is a debilitating disease of the pleural cavity. It is primarily associated with previous inhalation of asbestos fibers. These fibers initiate an oxidant coupled inflammatory response. Repeated exposure to asbestos fibers results in a prolonged inflammatory response and cycles of tissue damage and repair. The inflammation-associated cycles of tissue damage and repair are intimately involved in the development of asbestos-associated cancers. Macrophages are a key component of asbestos-associated inflammation and play essential roles in the etiology of a variety of cancers. Macrophages are also a source of C-C motif chemokine ligand 2 (CCL2), and a variety of tumor-types express CCL2. High levels of CCL2 are present in the pleural effusions of mesothelioma patients, however, CCL2 has not been examined in the serum of mesothelioma patients.Methods The present study was carried out with 50 MPM patients and 356 subjects who were possibly exposed to asbestos but did not have disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. The levels of CCL2 in the serum of the study participants was determined using ELISA.Results Levels of CCL2 were significantly elevated in the serum of the MPM patients, and the increase was dependent on the stage of the disease.Conclusions Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Several, but not all, studies of serum CCL2 levels in patients with other types of cancer also report elevated serum CCL2, and many of these studies report that the increased levels of serum CCL2 are associated with the stage of the disease. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

scholarly journals Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

2019 ◽  
Author(s):  
Takumi Kishimoto ◽  
Nobukazu Fujimoto ◽  
Takeshi Ebara ◽  
Toyonori Omori ◽  
Tetsuya Oguri ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Malignant Pleural Mesothelioma ◽  
Tissue Damage ◽  
Serum Levels ◽  
Pleural Mesothelioma ◽  
Asbestos Fibers ◽  
Chemokine Ligand ◽  
History Of ◽  
Tumor Types ◽  
Study Participants

Abstract Background: Malignant pleural mesothelioma (MPM) is a debilitating disease of the pleural cavity. It is primarily associated with previous inhalation of asbestos fibers. These fibers initiate an oxidant coupled inflammatory response. Repeated exposure to asbestos fibers results in a prolonged inflammatory response and cycles of tissue damage and repair. The inflammation-associated cycles of tissue damage and repair are intimately involved in the development of asbestos-associated cancers. Macrophages are a key component of asbestos-associated inflammation and play essential roles in the etiology of a variety of cancers. Macrophages are also a source of C-C motif chemokine ligand 2 (CCL2), and a variety of tumor-types express CCL2. High levels of CCL2 are present in the pleural effusions of mesothelioma patients, however, CCL2 has not been examined in the serum of mesothelioma patients. Methods: The present study was carried out with 50 MPM patients and 356 subjects who were possibly exposed to asbestos but did not have disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. The levels of CCL2 in the serum of the study participants was determined using ELISA. Results: Levels of CCL2 were significantly elevated in the serum of patients with advanced MPM patients. Conclusions: Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

scholarly journals Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Takumi Kishimoto ◽  
Nobukazu Fujimoto ◽  
Takeshi Ebara ◽  
Toyonori Omori ◽  
Tetsuya Oguri ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Malignant Pleural Mesothelioma ◽  
Tissue Damage ◽  
Serum Levels ◽  
Pleural Mesothelioma ◽  
Asbestos Fibers ◽  
Chemokine Ligand ◽  
History Of ◽  
Tumor Types ◽  
Study Participants

Abstract Background Malignant pleural mesothelioma (MPM) is a debilitating disease of the pleural cavity. It is primarily associated with previous inhalation of asbestos fibers. These fibers initiate an oxidant coupled inflammatory response. Repeated exposure to asbestos fibers results in a prolonged inflammatory response and cycles of tissue damage and repair. The inflammation-associated cycles of tissue damage and repair are intimately involved in the development of asbestos-associated cancers. Macrophages are a key component of asbestos-associated inflammation and play essential roles in the etiology of a variety of cancers. Macrophages are also a source of C-C motif chemokine ligand 2 (CCL2), and a variety of tumor-types express CCL2. High levels of CCL2 are present in the pleural effusions of mesothelioma patients, however, CCL2 has not been examined in the serum of mesothelioma patients. Methods The present study was carried out with 50 MPM patients and 356 subjects who were possibly exposed to asbestos but did not have disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. The levels of CCL2 in the serum of the study participants was determined using ELISA. Results Levels of CCL2 were significantly elevated in the serum of patients with advanced MPM. Conclusions Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

scholarly journals Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

2019 ◽  
Author(s):  
Takumi Kishimoto ◽  
Nobukazu Fujimoto ◽  
Takeshi Ebara ◽  
Toyonori Omori ◽  
Tetsuya Oguri ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Malignant Pleural Mesothelioma ◽  
Tissue Damage ◽  
Serum Levels ◽  
Pleural Mesothelioma ◽  
Asbestos Fibers ◽  
Chemokine Ligand ◽  
History Of ◽  
Tumor Types ◽  
Study Participants

Abstract Background: Malignant pleural mesothelioma (MPM) is a debilitating disease of the pleural cavity. It is primarily associated with previous inhalation of asbestos fibers. These fibers initiate an oxidant coupled inflammatory response. Repeated exposure to asbestos fibers results in a prolonged inflammatory response and cycles of tissue damage and repair. The inflammation-associated cycles of tissue damage and repair are intimately involved in the development of asbestos-associated cancers. Macrophages are a key component of asbestos-associated inflammation and play essential roles in the etiology of a variety of cancers. Macrophages are also a source of C-C motif chemokine ligand 2 (CCL2), and a variety of tumor-types express CCL2. High levels of CCL2 are present in the pleural effusions of mesothelioma patients, however, CCL2 has not been examined in the serum of mesothelioma patients. Methods: The present study was carried out with 50 MPM patients and 356 subjects who were possibly exposed to asbestos but did not have disease symptoms and 41 healthy volunteers without a history of exposure to asbestos. The levels of CCL2 in the serum of the study participants was determined using ELISA. Results: Levels of CCL2 were significantly elevated in the serum of patients with advanced MPM patients. Conclusions: Our findings are consistent with the premise that the CCL2/CCR2 axis and myeloid-derived cells play an important role in MPM and disease progression. Therapies are being developed that target CCL2/CCR2 and tumor resident myeloid cells, and clinical trials are being pursued that use these therapies as part of the treatment regimen. The results of trials with patients with a similar serum CCL2 pattern as MPM patients will have important implications for the treatment of MPM.

scholarly journals Serum Levels of Alpha-Tocopherol, Vitamin C, Beta-Carotene, and Retinol in Malignant Pleural Mesothelioma

2012 ◽  
Vol 13 (7) ◽  
pp. 3025-3029 ◽  
Author(s):  
Salih Emri ◽  
Saadettin Kilickap ◽  
Cem Kadilar ◽  
Meltem Gulhan Halil ◽  
Hadi Akay ◽  
...  
Keyword(s):  
Vitamin C ◽  
Malignant Pleural Mesothelioma ◽  
Beta Carotene ◽  
Serum Levels ◽  
Alpha Tocopherol ◽  
Pleural Mesothelioma

scholarly journals Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
James Benjamin Gleason ◽  
Basheer Tashtoush ◽  
Maria Julia Diacovo
Keyword(s):  
Computed Tomography ◽  
Malignant Pleural Mesothelioma ◽  
Asbestos Exposure ◽  
Pleural Mesothelioma ◽  
Ct Guided ◽  
Core Needle ◽  
Chest Computed Tomography ◽  
History Of ◽  
Sarcomatoid Mesothelioma ◽  
Histologic Component

Biphasic malignant pleural mesothelioma is a rare malignant tumor, usually presenting as a pleural-based mass in a patient with history of chronic asbestos exposure. We herein report a case of a 41-year-old man who presented with chest pain and had a chest computed tomography (CT) scan suggestive of a primary skeletal tumor originating from the ribs (chondrosarcoma or osteosarcoma), with no history of asbestos exposure. CT-guided core needle biopsies were diagnosed as malignant sarcomatoid mesothelioma. Surgical resection and chest wall reconstruction were performed, confirming the diagnosis and revealing a secondary histologic component (epithelioid), supporting the diagnosis of biphasic malignant mesothelioma.

scholarly journals A case of primary immunodeficiency: hyper IgM syndrome

2019 ◽  
Vol 6 (6) ◽  
pp. 2700
Author(s):  
Madhura P. Fadnis ◽  
Pratibha B. Shamkuwar
Keyword(s):  
Respiratory Tract Infections ◽  
Elevated Serum ◽  
Serum Levels ◽  
Present Case Report ◽  
Class Switch ◽  
Hyper Igm Syndrome ◽  
History Of ◽  
Hyper Igm ◽  
Tract Infections ◽  
Recurrent Respiratory Tract Infections

Hyper IgM syndrome are group to disorders characterized by elevated serum level of IgM and low or absent serum levels of IgG, IgA and IgE the mechanism of HIGM is immunoglobulin Class-Switch Recombination (CSR) failure and Somatic Hyper Mutation (SHM). This diagnosis should be considered in any patient presenting with hypogammaglobulinemia, with low or absent IgG and IgA and normal or elevated IgM level. In the present case report, this was a 6-year-old male child who had history of recurrent respiratory tract infections who presented with otitis media and persistent fever spikes. Immunoglobulin studies revealed a pattern consistent with hyper IgM.

scholarly journals Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
Reiko Ideguchi ◽  
Kazuto Ashizawa ◽  
Saori Akashi ◽  
Michiko Shindo ◽  
Kazunori Minami ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Mesothelioma ◽  
Histopathological Examination ◽  
Lymphatic Spread ◽  
Mediastinal Lymphadenopathy ◽  
Pleural Mesothelioma ◽  
Pleural Thickening ◽  
History Of ◽  
Pulmonary Parenchyma ◽  
Lymphangitic Carcinomatosis

We herein report two cases of malignant pleural mesothelioma with marked lymphangiosis. The patients included a 68-year-old man and a 67-year-old man who both had a history of exposure to asbestos. Computed tomography (CT) on admission showed pleural effusion with pleural thickening. In both cases, a histopathological examination of the pleura confirmed the diagnosis of epithelioid malignant mesothelioma. They received chemotherapy, but the treatment was only palliative. The chest CT assessments during admission revealed marked pleural effusion and mediastinal lymphadenopathy. CT also showed a consolidative mass with bronchovascular bundle and septal thickening in the lungs suggesting pulmonary parenchymal involvement and the lymphangitic spread of the tumor. These CT findings mimicked lung cancer with pleuritis and lymphangitic carcinomatosis. Autopsy was performed in both cases. Macroscopically, the tumor cells infiltrated the lung with the marked lymphatic spread of the tumor. Microscopy also revealed that the tumor had invaded the pulmonary parenchyma with the marked lymphatic spread of the tumor. Although this growth pattern is unusual, malignant pleural mesothelioma should be considered as the differential diagnosis, especially in patients with pleural lesions.

scholarly journals MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Paola Mozzoni ◽  
Luca Ampollini ◽  
Matteo Goldoni ◽  
Rossella Alinovi ◽  
Marcello Tiseo ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Molecular Mechanisms ◽  
Prognostic Biomarkers ◽  
Pleural Mesothelioma ◽  
Diagnostic Biomarkers ◽  
Asbestos Fibers ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Patient Prognosis

Background. The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying the disease development and progression.Aims. To identify a pattern of miRNAs as possible diagnostic biomarkers for patients with malignant pleural mesothelioma (MPM) and asbestosis (ASB) and as prognostic biomarkers for MPM patients.Methods. miRNA-16, miRNA-17, miRNA-126, and miRNA-486 were quantified in plasma and formalin-fixed paraffin-embedded samples to evaluate their diagnostic and prognostic roles compared to patients with other noncancerous pulmonary diseases (controls). Results. The expression of all the miRNAs was significantly lower in patients with MPM and ASB than that in controls. miRNA-16, miRNA-17, and miRNA-486 in plasma and tissue of MPM patients were significantly correlated. Furthermore, the expression of miRNA-16 in plasma and tissue, and miRNA-486 only in tissue, was positively related with cumulative survival in MPM patients.Conclusions. All the miRNA levels were decreased in patients with MPM or ASB, supporting the role of circulating miRNAs as a potential tool for diseases associated with exposure to asbestos fibers. miRNA-16 was directly related to MPM patient prognosis, suggesting its possible use as a prognostic marker in MPM patients.

A European multicentre, placebo-controlled supplementation study with α-tocopherol, carotene-rich palm oil, lutein or lycopene: analysis of serum responses

2002 ◽  
Vol 102 (4) ◽  
pp. 447-456 ◽  
Author(s):  
Begoña OLMEDILLA ◽  
Fernando GRANADO ◽  
Susan SOUTHON ◽  
Anthony J.A. WRIGHT ◽  
Inmaculada BLANCO ◽  
...  
Keyword(s):  
Side Effects ◽  
Palm Oil ◽  
Tissue Damage ◽  
Elevated Serum ◽  
Fold Increase ◽  
Serum Levels ◽  
Dose Time ◽  
Isomer Distribution ◽  
Serum Response ◽  
Β Carotene

Increased levels of oxidative stress have been implicated in tissue damage and the development of chronic diseases, and dietary antioxidants may reduce the risk of oxidative tissue damage. As part of a European multicentre project, several studies were undertaken with the aim of testing whether the consumption of foods rich in carotenoids reduces oxidative damage to human tissue components. We describe here the serum response of carotenoids and tocopherols upon supplementation with carotenoids from natural extracts (α-carotene+β-carotene, lutein or lycopene; 15mg/day) and/or with α-tocopherol (100mg/day) in a multicentre, placebo-controlled intervention study in 400healthy male and female volunteers, aged 25-45 years, from five European regions (France, Northern Ireland, Republic of Ireland, The Netherlands and Spain). Supplementation with α-tocopherol increased serum α-tocopherol levels, while producing a marked decrease in serum γ-tocopherol. Supplementation with α- + β-carotene (carotene-rich palm oil) resulted in 14-fold and 5-fold increases respectively in serum levels of these carotenoids. Supplementation with lutein (from marigold extracts) elevated serum lutein (approx. 5-fold), zeaxanthin (approx. doubled) and ketocarotenoids (although these were not present in the supplement), whereas lycopene supplementation (from tomato paste) resulted in a 2-fold increase in serum lycopene. The isomer distributions of β-carotene and lycopene in serum remained constant regardless of the isomer composition in the capsules. In Spanish volunteers, additional data showed that the serum response to carotenoid supplementation reached a plateau after 4 weeks, and no significant side effects (except carotenodermia) or changes in biochemical or haematological indices were observed throughout the study. This part of the study describes dose-time responses, isomer distribution, subject variability and side effects during supplementation with the major dietary carotenoids in healthy subjects.

Sign in / Sign up

Export Citation Format

Share Document